HCV Post-Exposure Prophylaxis for Health Care Workers

Massachusetts General Hospital

Overview

This is an unblinded, observational trial of sofosbuvir-velpatasvir in adult health care workers who are exposed to hepatitis C virus from needlestick injury with hollow-bore needles.

The goal of this study is to assess the safety and tolerability of the use of sofosbuvir-velpatasvir in the setting of post-exposure prophylaxis among Health Care Workers exposed to HCV from needlestick injury with hollow-bore needles

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Conditions

Hepatitis C

Interventions

Sofosbuvir/Velpatasvir Treatment for 14 daysDRUG

14 day therapy with Sofosbuvir/Velpatasvir

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Healthcare worker with exposure through needlestick injury with hollow-bore needles to source patients who are HCV positive * Healthcare worker must be HCV Ab- Exclusion Criteria: * HCV Ab positive * HCV Ab negative and HCV RNA greater than 1000 IU/ml * Active malignancy * Positive urine pregnancy test

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Undetectable HCV RNA

Negative HCV viral RNA at 12 weeks after the last dose of treatment.

Time frame: 12 weeks post treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.